Drug discovery on an unprecedented scale [caption id="" align="aligncenter" width="700"] Artistic impression of artificial intelligence in drug design - ©Ina Pöhner[/caption] Boosting virtual screening with machine learning allowed for a 10-fold time reduction in the processing of 1.56 billion drug-like molecules. Researchers from the University of Eastern Finland teamed up with industry…..
Transposons: From ‘selfish’ genes to key elements in biological processes A new SISSA and IIT study reveals unexpected functionality of LINE transposons, paving new paths in the search for cures for neurodevelopmental and ageing disorders. Double Helix generated by AI - ©Remo Sanges In 2001 the sequencing of the…..
Broken String Biosciences Closes $15M Series A Funding Round Broken String Biosciences, a UK-based genomics company building a technology platform to drive the development of cell and gene therapies that are safer by design, has closed a $15 million Series A investment round, co-led by Illumina Ventures and Mérieux Equity…..
NIH clinical trial of universal flu vaccine candidate begins A colorized transmission electron micrograph of influenza A virus particles, colorized orange, isolated from a patient sample and then propagated in cell culture. ©NIAID Enrollment in a Phase 1 trial of a new investigational universal influenza vaccine candidate has begun at…..
AlveoGene to develop inhaled gene therapies for rare respiratory diseases AlveoGene is a new gene therapy company created and funded by Oxford Science Enterprises, Harrington Discovery Institute and Old College Capital in partnership with six leading scientists from the UK Respiratory Gene Therapy Consortium (GTC). The Oxford-based company will use…..
MaaT Pharma and Skyepharma Complete Construction of Europe’s Largest Manufacturing Facility for Microbiome Ecosystem Therapies
MaaT Pharma and Skyepharma Complete Construction of Europe’s Largest Manufacturing Facility for Microbiome Ecosystem Therapies • Major milestone achieved with new state-of-the-art microbiome facility spanning over 1600 m², completed within the 12-month timeframe, further enhancing bioproduction capabilities and contributing to the ecosystem in France and Europe. • MaaT Pharma is…..